Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome

British Journal of Dermatology

Volumn 164, Issue 3, 2011, Pages 521-529

  Siegel, D H ^a   McKenzie, J ^b   Frieden, I J ^c   Rauen, K A ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2;

ADOLESCENT; ADULT; ARTICLE; BRAF GENE; CAFE AU LAIT SPOT; CAPILLARY HEMANGIOMA; CARDIOFACIOCUTANEOUS SYNDROME; CHILD; CLINICAL FEATURE; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC DISORDER; HEALTH SURVEY; HUMAN; HYPERKERATOSIS; KERATOSIS PILARIS; KRAS GENE; MAJOR CLINICAL STUDY; MALE; MAP2K1 GENE; MAP2K2 GENE; MELANOCYTIC NEVUS; PAPILLOMA; PRIORITY JOURNAL; SCHOOL CHILD; SKIN DISEASE; ULERYTHEMA OPHRYOGENES;

ABNORMALITIES, MULTIPLE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; ECTODERMAL DYSPLASIA; FACIES; FAILURE TO THRIVE; FEMALE; GERM-LINE MUTATION; HAIR DISEASES; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SKIN ABNORMALITIES; YOUNG ADULT;

EID: 79952429680     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10122.x     Document Type: Article

References (39)

1. Tidyman WE, Rauen KA,. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 2008; 10: e37.
2. Tidyman WE, Rauen KA,. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009; 19: 230-6.
3. Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006; 38: 294-6.
4. Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006; 311: 1287-90. (Pubitemid 43334718)
5. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29: 465-8. (Pubitemid 34326699)
6. Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007; 39: 70-4. (Pubitemid 46026503)
7. Tartaglia M, Pennacchio LA, Zhao C, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007; 39: 75-9. (Pubitemid 46026504)
8. Razzaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007; 39: 1013-17. (Pubitemid 47185179)
9. Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007; 39: 1007-12. (Pubitemid 47185177)
10. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006; 38: 331-6.
11. Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005; 37: 1038-40. (Pubitemid 41486653)
12. Digilio MC, Conti E, Sarkozy A, et al. Grouping of multiple-lentigines/ LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002; 71: 389-94. (Pubitemid 34800254)
13. Sarkozy A, Carta C, Moretti S, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat 2009; 30: 695-702.
14. Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation- arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003; 73: 1240-9. (Pubitemid 38037418)
15. Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990; 62: 193-201.
16. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990; 62: 187-92.
17. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990; 249: 181-6.
18. Brown SJ, Relton CL, Liao H, et al. Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. Br J Dermatol 2009; 161: 884-9.
19. Kilcline C, Frieden IJ,. Infantile hemangiomas: how common are they? A systematic review of the medical literature Pediatr Dermatol 2008; 25: 168-73. (Pubitemid 351579596)
20. Tidyman WE, Rauen KA,. Molecular causes of cardio-facio-cutaneous syndrome. In: Monographs in Human Genetics: Noonan Syndrome and Related Disorders-A Matter of Deregulated Ras Signaling (, Zenker M, ed.), Vol. 17. Basel: Karger, 2009; 73-82.
21. Crane LA, Mokrohisky ST, Dellavalle RP, et al. Melanocytic nevus development in Colorado children born in 1998: a longitudinal study. Arch Dermatol 2009; 145: 148-56.
22. Bataille V, Bishop JA, Sasieni P, et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73: 1605-11. (Pubitemid 26235392)
23. Csoma Z, Erdei Z, Bartusek D, et al. [The prevalence of melanocytic naevi among teenagers]. Orv Hetil 2008; 149: 2173-82.
24. Bos JL,. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9. (Pubitemid 19213607)
25. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-22. (Pubitemid 29080340)
26. Terao M, Sakai N, Higashiyama S, et al. Cutaneous symptoms in a patient with cardiofaciocutaneous syndrome and increased ERK phosphorylation in skin fibroblasts. Br J Dermatol 2010; 163: 881-4.
27. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451-5. (Pubitemid 35364105)
28. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934. (Pubitemid 34976022)
29. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20. (Pubitemid 36068675)
30. Estep AL, Palmer C, McCormick F, et al. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE 2007; 2: e1279.
31. Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008; 68: 5524-8.
32. Armour CM, Allanson JE,. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J Med Genet 2008; 45: 249-54. (Pubitemid 351518732)
33. McKee P, (ed.). Pathology of the Skin, Vol. 1. Amsterdam: Elsevier, 2005.
34. Nguyen V, Buka RL, Roberts BJ, et al. Cutaneous manifestations of Costello syndrome. Int J Dermatol 2007; 46: 72-6. (Pubitemid 46029730)
35. North PE, Mizeracki A, Mihm MC Jr, et al. GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma. Clin Neuropathol 2000; 19: 131-7. (Pubitemid 30304180)
36. North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11-22. (Pubitemid 30054381)
37. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555-9.
38. Gonzalez ME, Blanco FP, Garzon MC,. Verrucous papules and plaques in a pediatric patient: cutaneous papillomas associated with Costello syndrome. Arch Dermatol 2007; 143: 1201-6.
39. Martinelli S, De Luca A, Stellacci E, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 2010; 87: 250-7.